Acquired thrombotic risk factors in the critical care setting

Critical Care Medicine

Volumn 38, Issue SUPPL. 2, 2010, Pages

  Ortel, Thomas L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acquired; Risk; Thrombocytopenia; Thromboprophylaxis; Thrombosis; Venous thromboembolism

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTIVITAMIN K; ARGATROBAN; DANAPAROID; ERYTHROPOIETIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN; THROMBIN INHIBITOR; WARFARIN;

ACQUIRED THROMBOTIC RISK; ANEMIA; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; CARDIOVASCULAR RISK; CENTRAL VENOUS CATHETER; COMPRESSION GARMENT; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG WITHDRAWAL; ENTERITIS; HEPARIN INDUCED THROMBOCYTOPENIA; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; IMMOBILIZATION; INDWELLING CATHETER; INJURY; INTENSIVE CARE; INTENSIVE CARE UNIT; LOW DRUG DOSE; LUNG EMBOLISM; METABOLIC SYNDROME X; MYELOPROLIFERATIVE DISORDER; NEOPLASM; NEPHROTIC SYNDROME; OBESITY; POSTOPERATIVE PERIOD; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 74949098518     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181c9ccc8     Document Type: Review

References (81)

1. Heit J, Silverstein M, Mohr D, et al: The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86:452-463
2. Ageno W, Bacattini C, Brighton T, et al: Cardiovascular risk factors and venous thrombo-embolism. A meta-analysis. Circulation 2008; 117:93-102
3. White R, Zhou H, Romano P: Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90:446-455
4. Geerts W, Bergqvist D, Pineo G, et al: Pre-vention of venous thromboembolism. Chest 2008; 133(6 suppl):381S-453S
5. Anderson FA Jr, Spencer FA: Risk factors for venous thromboembolism. Circulation 2003; 107:I-9-I-16
6. Lyman G, Khorana A, Falanga A, et al: American Society of Clinical Oncology Guideline: Recommendations for venous thromboem-bolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505 (Pubitemid 350232226)
7. Rocha A, de Vasconcellos A, da Luz Neto E, et al: Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obesity Surg 2006; 16:1645-1655
8. Ettema H, Hoppener M, Veeger N, et al: Low incidence of venographically detected deep vein thrombosis after knee arthroscopy without thromboprophylaxis: a prospective cohort study. J Thromb Haemost 2006; 4:1411-1413 (Pubitemid 43756725)
9. Frederiksen S, Hedenbro J, Norgren L: Enox-aparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003; 90:547-548
10. Knudson M, Collins J, Goodman S, et al: Thromboembolism following multiple trauma. J Trauma 1992; 92:2-11
11. Geerts W, Code K, Jay R, et al: A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994; 331: 1601-1606
12. Shackford S, Davis J, Hollingsworth-Frid-lund P, et al: Venous thromboembolism in patients with major trauma. Am J Surg 1990; 159:365-369
13. Knudson M, Ikossi D, Khaw L, et al: Throm-boembolism after trauma. An analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. Ann Surg 2004; 240:490-498
14. Adams R, Hamrick M, Berenguer C, et al: Four years of an aggressive prophylaxis and screening protocol for venous thromboem-bolism in a large trauma population. J Trauma 2008; 65:300-308
15. Giannoudis PV, Pountos I, Pape HC, et al: Safety and efficacy of vena cava filters in trauma patients. Injury 2007; 38:7
16. Albers G, Amarenco P, Easton J, et al: Anti-thrombotic and thrombolytic therapy for ischemic stroke. Chest 2008; 133:630S-669S
17. The Clots Trial Collaboration: effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): A multicentre, randomized controlled trial. Lancet 2009; 373:1958-1965
18. Chandra D, Parisini E, Mozaffarian D: Meta-analysis: Travel and risk for venous throm-boembolism. Ann Intern Med 2009; 151: 180-190
19. Schreijer A, Cannegieter S, Doggen C, et al: The effect of flight-related behaviour on the risk of venous thrombosis after air travel. Br J Haematol 2008; 144:425-429
20. Burns K, McLaren A: A critical review of thromboembolic complications associated with central venous catheters. Can J An-aesth 2008; 55:532-541
21. Rocha A, Tapson V: Venous thromboembo-lism in intensive care patients. Clin Chest Med 2003; 24:103-122
22. Goldenberg N, Bernard T: Venous thrombo-embolism in children. Pedaiatr Clin North Am 2008; 55:305-322
23. Timsit J-F, Farkas J-C, Boyer J-M, et al: Central vein catheter-related thrombosis in intensive care patients. Incidence, risks factors, and relationship with catheter-related sepsis. Chest 1998; 114:207-213
24. Verso M, Agnelli G: Venous thromboembo-lism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21:3665-3675
25. Chan M: Hemodialysis central venous catheter dysfunction. Semin Dialysis 2008; 21: 516-521
26. Jain G, Allon M, Saddekni S, et al: Does heparin coating improve patency or reduce infection of tunneled dialysis catheters? Clin J Am Soc Nephrol 2009; 4:1787-1790
27. Grove J, Pevec W: Venous thrombosis related to peripherally inserted central catheters. J Vasc Interv Radiol 2000; 11:837-840
28. Kirkpatrick A, Rathbun S, Whitsett T, et al: Prevention of central venous catheter-associated thrombosis: A meta-analysis. Am J Med 2007; 120:901-910
29. Monreal M, Raventos AL, Ruiz J, et al: Pulmonary embolism in patients with upper extremity DVT associated to venous central lines-a prospective study. Thromb Haemost 1994; 72:548-550
30. Prandoni P, Polistena P, Bernardi E, et al: Upper-extremity deep vein thrombosis. Risk factors, diagnosis and complications. Arch Intern Med 1997; 157:57-62
31. Khorana A, Francis C, Culakova E: Throm-boembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5:632-634
32. De Stefano V, Za T, Rossi E, et al: Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments. Haematologica 2008; 93:372-380
33. Vannucchi A, Barbui T: Thrombocytosis and thrombosis. Hematology Am Soc Hematol Educ Program 2007; 363-370
34. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054
35. Dentali F, Squizzato A, Brivio L, et al: JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: A meta-analysis. Blood 2009; 113:5617-5623
36. Akca S, Haji-Michael P, de Mendonca A, et al: Time course of platelet counts in critically ill patients. Crit Care Med 2002; 30:753-756
37. Valade N, Decailliot F, Rebufat Y, et al: Throm-bocytosis after trauma: Incidence, aetiology, and clinical significance. Br J Anaesth 2005; 94:18-23
38. Brodsky R: Paroxysmal nocturnal hemoglo-binuria: stem cells and clonality. Hematol-ogy Am Soc Hematol Educ Program. 2008; 111-115
39. Nishimura J, Kanakura Y, Ware R, et al: Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine 2004; 83:193-207
40. Arepally GM, Ortel TL: Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809-817
41. Selleng K, Warkentin T, Greinacher A: Hep-arin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007; 35: 1165-1176
42. Lubenow N, Kempf R, Eichner A, et al: He-parin-induced thrombocytopenia: Temporal pattern of thrombocytopenia in relation to initial use or re-exposure to heparin. Chest 2002; 122:37-42
43. Warkentin T, Kelton J: Delayed-onset hepa-rin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135:502-506
44. Warkentin T, Sheppard J, Moore J, et al: Quantitative interpretation of optical density measurements using PF4-dependent en-zyme-immunoassays. J Thromb Haemost 2008; 6:1304-1312
45. Whitlatch N, Perry S, Ortel T: Anti-heparin/ platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocyto-penia. Thromb Haemost 2008; 100:678-684
46. Warkentin T, Greinacher A, Koster A: Biva-lirudin. Thromb Haemost 2008; 99:830-839
47. Jordan W: Pulmonary embolism. Lancet 1961; 1146-1147
48. Rosendaal F, Helmerhorst F, Vandenbroucke J: Female hormones and thrombosis. Arte-rioscler Thromb Vasc Biol 2002; 22:201-210
49. van Hylckama Vlieg A, Helmerhorst F, Van-denbroucke J, et al: The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921
50. Lidegaard O, Lokkegaard E, Svendsen A, et al: Hormonal contraception and risk of venous thromboembolism: National follow-up study. BMJ 2009; 339:b2890
51. Mohllajee A, Curtis K, Martins S, et al: Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembo-lism? A systematic review. Contraception 2006; 73:166-178
52. Beral V, Banks E, Reeves G: Evidence from randomized trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360:942-944
53. Canonico M, Plu-Bureau G, Lowe G, et al: Hormone replacement therapy and risk of venous thromboembolism in postmeno-pausal women: Systematic review and meta-analysis. BMJ 2008; 336:1227-1231
54. Cuzick J, Powles T, Veronesi U, et al: Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361:296-300
55. Deitcher S, Gomes M: The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma. A systematic review. Cancer 2004; 101:439-449 (Pubitemid 38970595)
56. Hernandez R, Sorensen H, Pedersen L, et al: Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism. A Danish population-based cohort study. Cancer 2009; 115:4442-4449
57. Lycette J, Luoh S-W, Beer T, et al: Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature. Breast Cancer Res Treat 2006; 99:249-255
58. Khorana A, Francis C, Culakova E, et al: Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110:2339-2346
59. Ramzi N, Accaoui E, Shamseddeen W, et al: Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007; 97: 1031-1036
60. Palumbo A, Rajkumar S, Dimopoulos M, et al: Prevention of thalidomide-and lenalido-mide-associated thrombosis in myeloma. Leukemia 2008; 22:414-423
61. Nalluri S, Chu D, Keresztes R, et al: Risk of venous thromboembolism with the angio-genesis inhibitor bevacizumab in cancer patients. A meta-analysis. JAMA 2008; 300: 2277-2285
62. Kuderer N, Ortel T, Francis C, et al: Venous thromboembolism and bleeding in cancer patients on bevacizumab therapy: A meta-analysis. J Thromb Haemost 2009; 7 (Suppl 2):P-MO-492
63. Bennett C, Silver S, Djulbegovic B, et al:Venous thromboembolism and mortality associated with recombinant erythropoietin and darbopoietin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914-924
64. Corwin H, Gettinger A, Fabian T, et al: Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357:965-976
65. Zarychanski R, Turgeon A, McIntyre L, et al: Erythropoietin-receptor agonists in critically ill patients: A meta-analysis of randomized controlled trials. CMAJ 2007; 177:725-734
66. Phrommintikul A, Haas S, Elsik M, et al: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 2007; 369:381-388
67. O'Connell K, Wood J, Lozier J, et al: Throm-boembolic adverse events after use of recom-binant human coagulation factor VIIa. JAMA 2006; 295:293-298
68. Singhal R, Brimble K: Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res 2006; 118:397-407
69. Cherng S, Huang W, Wang Y, et al: The role of lung scintigraphy in the diagnosis of ne-phrotic syndrome with pulmonary embolism. Clin Nucl Med 2000; 25:167-172
70. Bernstein C, Blanchard J, Houston D, et al: The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population-based cohort study. Thromb Haemost 2001; 85:430-434
71. Prandoni P, Bilora F, Marchiori A, et al: An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-1441
72. van der Hagen P, Folsom A, Jenny N, et al: Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost 2006; 4:1903-1908 (Pubitemid 44226766)
73. Hansson P-O, Eriksson H, Welin L, et al: Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: "The study of men born in 1913." Arch Intern Med 1999; 159: 1886-1890
74. Goldhaber S, Grodstein F, Stampfer M, et al: A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277: 642-645 (Pubitemid 27097428)
75. Goldhaber S, Tapson V, Committee for the DVT Free Study Group: A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Car-diol. 2004; 93:259-262
76. Pomp E, Rosendaal F, Doggen C: Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008; 83:97-102
77. Severinsen M, Kristensen S, Johnsen S, et al: Smoking and venous thromboembolism: A Danish follow-up study. J Thromb Haemost 2009; 7:1297-1303
78. Heit J, Leibson C, Ashrani A, et al: Is diabetes mellitus an independent risk factor for venous thromboembolism? A population-based case-control study. Arterioscler Thromb Vasc Biol 2009; 29:1399-1405
79. Grundy SM, Cleeman JI, Daniels SR, et al: Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735-2752
80. Borch K, Braekkan S, Mathiesen E, et al: Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: The Tromso study. J Thromb Haemost 2009; 7:739-745
81. Steffen L, Cushman M, Peacock J, et al: Metabolic syndrome and risk of venous throm-boembolism: Longitudinal investigation of thromboembolism etiology. J Thromb Hae-most 2009; 7:746-751